Abstract
Introduction
It is well known that L -carnitine is a transporter of long-chain fatty acids into mitochondria, especially in skeletal and cardiac muscle tissues, which rely on fatty acids as an energy source under aerobic metabolic conditions [1] . Carnitine administration has been reported to be beneficial in patients with angina, ischemia-induced cardiac insufficiency, cardiogenic shock, cardiomyopathy and myocardial infarction [2] .
The concentration of plasma and tissue carnitine in chronic hemodialysis patients decreases severely because of its impaired synthesis in the kidney and liver, as well as due to great losses across the dialysis membrane during hemodialysis [2] [3] [4] [5] . It has also been reported that hypocarnitinemia is closely related to cardiomegaly and cardiac ischemia in these patients [6, 7] . Therefore, an improvement in cardiac function of patients with chronic hemodialysis associated with carnitine therapy might be expected. However, the results of previous studies are conflicting [8] [9] [10] [11] .
Cardiovascular disease is a common finding in dialysis patients, accounting for 40% of deaths in this population [12] . It is important to clarify the effects of L -carnitine supplementation on the hemodynamic state of dialysis patients in terms of morbidity and mortality. In order to investigate whether the supplementation of L -carnitine might be associated with beneficial effects on cardiac function and clinical status of dialysis patients, a randomized double-blind placebo-controlled study was performed.
Methods

Subjects
Twenty stable and ambulatory hemodialysis patients were studied. The inclusion criteria were as follows: chronic hemodialysis for more than 2 years, dialysis frequency or duration unchanged for the previous 3 months, and stable laboratory data without severe anemia or hyperparathyroidism. Patients with prior myocardial infarction or valvular heart disease were excluded. The patients were randomly assigned either to an active treatment group (900 mg L -carnitine p.o. daily for 3 months) or a placebo group under double-blind conditions. In order to ascertain stable hemodynamic conditions, the real drug was administered after a 1-month observation period. In all patients, hematological parameters were measured every month during the study period. Plasma levels of total and free carnitine were determined at baseline and after 3 months of treatment according to the enzyme cycling method. The study protocol was approved by the local ethics committee and conformed to the recommendations of the Declaration of Helsinki. Written informed consent was obtained from each patient.
Echocardiographic Examination
The Toshiba Xario SSA-660A (Toshiba, Odawara, Japan) was used to determine cardiac function. Left ventricular ejection fraction and Tei index calculated from ejection time and the interval between cessation and onset of mitral inflow were measured using a 2.5-MHz transducer. Diastolic function of the left ventricle was measured in the supine position with pulsed Doppler echocardiography. The ratio of early ventricular filling (E) and late ventricular filling (A) velocities of mitral inflow wave (E/A), the ratio of tissue Doppler annular early (e) and late (e') diastolic velocities (e/e'), and the ratio of peak systolic velocity (S) and peak anterograde diastolic velocity (D) of pulmonary venous waveforms (S/D) was evaluated. Left ventricular myocardial weight (LV mass) was calculated using the formula of Devereux. Echocardiography assessments were performed just after hemodialysis treatment at baseline and after 3 months of treatment. The same technician performed echocardiographic tests before and after the study period, without any previous information about the patient.
Episodes of Hypotension
Hypotension is defined as a drop in blood pressure necessitating a corrective intervention such as reduction in blood flow or negative pressure, or administration of saline or another medication. Hypotensive episodes were assessed every month during the study period.
Statistical Analysis
Descriptive results are shown as the mean ± standard deviation or standard error. Data were statistically analyzed by Student's t test for paired or unpaired samples and χ 2 test. A value of p < 0.05 was regarded as statistically significant.
Results
Baseline Patient Characteristics
After randomization, it became clear that 1 patient suffered from gastric cancer, and another patient experienced bone fracture accidentally. Because there were 2 dropouts, the remaining 18 patients were divided into a placebo group (n = 8) and an L -carnitine treatment group (n = 10). There were no differences in examined parameters between the placebo and the treated group ( table 1 ) . The dialysis procedure, including dialysis time, blood flow, dialysate flow, and dialyzer, were not changed during the study in both groups.
Plasma Carnitine Level
In the placebo group, free and acyl carnitine levels were 21.6 ± 7.9 and 17.4 ± 6.8 μmol/l at baseline, respectively, and 20.9 ± 7.8 and 17.2 ± 5.5 μmol/l after 3 months, respectively. In the treatment group, free and acyl carnitine levels were 22.3 ± 7.1 and 15.8 ± 2.8 μmol/l at baseline, respectively, and 140.3 ± 57.5 and 94.8 ± 50.4 μmol/l after 3 months, respectively. Differences in free and acyl carnitine levels at baseline versus after 3 months were highly significant (p < 0.001), representing a 6-fold increment in both cases ( fig. 1 a) .
The acyl/free carnitine ratio in the placebo group was 0.82 ± 0.19% at baseline and 0.83 ± 0.10% after 3 months. The acyl/free carnitine ratio in the treatment group decreased significantly from 0.80 ± 0.24% at baseline to 0.67 ± 0.13% after 3 months (p < 0.05). There was a significant difference in the acyl/free carnitine ratio between the placebo group and the treated group after 3 months of L -carnitine supplementation (p < 0.01; fig. 1 b) . 
Effect of Oral L -Carnitine Treatment on Cardiac Function
The ejection fraction significantly increased from 61.8 ± 16.0 to 64.4 ± 13.8% (p < 0.05) in the treated group ( fig. 2 ) . However, there was no difference in other echocardiographic parameters between the two groups ( table 2 ).
Effect of Oral L -Carnitine Treatment on Intradialytic Hypotension
Hypotensive episodes significantly decreased from 4.0 ± 1.7 to 1.3 ± 0.9 times per month (p < 0.05) after 3 months of L -carnitine supplementation, although the patients' body weight did not change significantly ( fig. 3 ) . 
Discussion
Study Protocol
Despite many trials, the results regarding the effects of L -carnitine supplementation on cardiac function of chronic hemodialysis patients are controversial [8] [9] [10] [11] . Some authors noted an improvement [13] [14] [15] [16] [17] , while others found no change [18] [19] [20] . Firstly, study limita- tions such as heterogeneity of the study group, non-randomized, non-double-blind studies, and investigators' potential bias must be taken into account. Therefore, a randomized double-blind placebo-controlled study was performed here, rather than an open observational study.
Secondly, it has been reported that the cardiac function of hemodialysis patients is influenced not only by preload and afterload, but also by the hemodialysis procedure itself [21] . In order to evaluate cardiac function accurately, echocardiography was performed just after the hemodialysis procedure in our study (not on a predialysis or non-dialysis day) to keep preload constant and minimize uremic toxins which are potential cardiac depressants. Thirdly, it is well known that there is a negative correlation between plasma carnitine levels and the duration of dialysis [7] . In addition, it has been reported that there is a bellshaped correlation between left ventricular hypertrophy and the duration of hemodialysis. Accordingly, patients with more than 2 years of hemodialysis treatment were selected in our study.
L -Carnitine and Cardiac Function
Only 1 randomized double-blind controlled study about the relationship of L -carnitine and cardiac function has been reported so far [18] . Fagher et al. [18] reported in 1985 that carnitine depletion is not responsible for cardiac dysfunction in patients on hemodialysis, but their patients had normal levels of skeletal and blood carnitine. Hemodialysis duration in their patients was not considered. Echocardiographic measurements were performed 16-18 h prior to dialysis. The duration of L -carnitine administration in their study was relatively short (6 weeks). In our study, it is not emphasized that L -carnitine has a positive inotropic effect, because the increase in the ejection fraction in the treated group was only 3% and statistical significance was marginal. However, taking the significant reduction of hypotensive episodes during the hemodialysis procedure into account, oral L -carnitine treatment might positively affect cardiac function even in patients with normal cardiac function.
In the systemic carnitine-deficient mouse [22] , electron microscopy demonstrated an increase in mitochondria and lipid droplets in the cardiac muscle. Compression or distortion of the myofibril bundles suggested the possibility of functional abnormalities of the cardiac muscle. The cardiac myocytes contain autolysosomes or autophagic vacuoles with electrondense membranous lamellar structures that are closely associated with mitochondria. Therefore, a potential reserve capacity of cardiac function might be damaged even in the phase of normal cardiac function assessed as total function. That might be the reason why a beneficial effect was observed in our study.
The echocardiographic parameters assessing diastolic cardiac function such as E/A, e/e', and S/D were not affected after L -carnitine supplementation in our study. It has been reported that left ventricular mass measured by magnetic resonance imaging was reduced after 6 months of L -carnitine treatment [16] . However, such a reduction was not observed in our study. It is possible that the morphological changes might take a relatively longer time.
L -Carnitine and Hypotension
Hypotension is a frequent complication in hemodialysis patients. Cardiac dysfunction is a factor contributing to the occurrence of dialysis hypotension. It has been reported [23] that patients in whom hypotension occurred frequently had a significantly higher mortality rate than those in whom intradialytic hypotension was absent. Several studies have shown a significant reduction in the incidence of intradialytic hypotension with L -carnitine treatment [24, 25] . Hypotensive episodes decreased significantly in our study, although patients' body 
